Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $23,680 | $0 | $0 | $139,709 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $826 | $0 | $0 | $0 |
| Gross Profit | $22,854 | $0 | $0 | $139,709 |
| % Margin | 96.5% | – | – | 100% |
| R&D Expenses | $241,647 | $163,032 | $118,499 | $88,248 |
| G&A Expenses | $120,879 | $66,922 | $33,258 | $25,241 |
| SG&A Expenses | $120,879 | $66,922 | $33,258 | $25,241 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $362,526 | $229,954 | $151,757 | $113,489 |
| Operating Income | -$339,672 | -$229,954 | -$151,757 | $26,220 |
| % Margin | -1,434.4% | – | – | 18.8% |
| Other Income/Exp. Net | $20,914 | $20,594 | $2,419 | -$1,294 |
| Pre-Tax Income | -$318,758 | -$209,360 | -$149,338 | $24,926 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$318,758 | -$209,360 | -$149,338 | $24,926 |
| % Margin | -1,346.1% | – | – | 17.8% |
| EPS | -3.73 | -2.98 | -2.46 | 0.48 |
| % Growth | -25.2% | -21.1% | -612.5% | – |
| EPS Diluted | -3.73 | -2.98 | -2.46 | 0.48 |
| Weighted Avg Shares Out | 85,622 | 70,371 | 60,761 | 52,065 |
| Weighted Avg Shares Out Dil | 85,622 | 70,371 | 60,761 | 52,065 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26,090 | $21,163 | $5,872 | $403 |
| Interest Expense | $4,929 | $208 | $3,137 | $1,899 |
| Depreciation & Amortization | $8 | $12 | $33 | $43 |
| EBITDA | -$313,821 | -$209,140 | -$146,168 | $26,868 |
| % Margin | -1,325.3% | – | – | 19.2% |